The Government Institutions Pension Fund (GIPF) has announced that as its contribution towards the fight against COVID-19 the company has invested N$7.8 million into FabuPharm (Pty) Ltd, a pharmaceutical company located in Otjiwarongo.
Fabupharm manufactures pharmaceutical products, not only for Namibia, but for international exports as well.
“We are particularly pleased to see that some of our unlisted investments in the pharmaceutical, healthcare, detergents, financial services, and food production, have meaningfully filled the gap when the country could not get supplies from the region and abroad during the lockdown,” said David Nuyoma, GIPF CEO and Principal Officer.
Nuyoma said that FabuPharm, among other drugs, manufactures immune boosters and other supplements, which have proven to be exceptional in boosting the immunity of Namibians in the fight against COVID-19.
Over the years, they expanded into a fullyfledged pharmaceutical manufacturer producing over 150 different products in nine product categories: 1. Internal Medicines – Registered products 2. Internal Products – Supplementary unregistered 3. Internal Veterinary Products 4. External Products – Topical treatments 5. Skin Care Creams 6. Disinfectant Products 7. External Products – Baby Range 8. Internal/ External 9. Speciality Products – Packed lines
“GIPF designed its COVID-19 assistance focusing on medium to long-term solutions and this is one of several investments towards investing into the production of essential goods and services not only for our members but for the nation at large,” stated Nuyoma.
In the photo: One of Fabupharm’s most famous product.
